Segment Information - Schedule of Revenue and Adjusted EBITDA by Segment (Details) - USD ($)	3 Months Ended				6 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Segment Revenue
Total revenue	$ 44,071,000		$ 49,999,000		$ 84,485,000	$ 110,863,000
Segment Adjusted EBITDA:
Total Adjusted EBITDA	(33,412,000)		(45,053,000)		(68,574,000)	(94,853,000)
Net loss	(59,103,000)	$ (69,400,000)	(75,270,000)	$ (104,624,000)	(128,503,000)	(179,894,000)
Adjustments:
Interest income, net	(2,009,000)		(3,752,000)		(4,583,000)	(8,059,000)
Other (income) expense, net	(15,000)		(145,000)		4,000	(477,000)
Provision for (benefit from) income taxes	(41,000)		36,000		(41,000)	36,000
Depreciation and amortization	4,972,000		4,474,000		8,983,000	8,951,000
Amortization of acquired intangible assets	1,775,000		3,638,000		3,551,000	7,277,000
Stock-based compensation expense	19,486,000		23,741,000		41,063,000	74,840,000
Loss on disposition of Lemonaid Health Limited and transaction-related costs	0		2,127,000		0	2,375,000
Litigation settlement cost	0		98,000		0	98,000
Cyber security incident expenses, net of probable insurance recoveries	1,523,000		0		10,952,000	0
Total Adjusted EBITDA	(33,412,000)		(45,053,000)		(68,574,000)	(94,853,000)
Corporate, Non-Segment
Segment Adjusted EBITDA:
Total Adjusted EBITDA	(12,804,000)		(12,156,000)		(26,708,000)	(25,215,000)
Consumer and Research Services
Segment Revenue
Total revenue	44,071,000		49,999,000		84,485,000	110,863,000
Consumer and Research Services | Operating Segments
Segment Adjusted EBITDA:
Total Adjusted EBITDA	(8,633,000)		(6,673,000)		(17,474,000)	(12,275,000)
Therapeutics
Segment Revenue
Total revenue	0		0		0	0
Therapeutics | Operating Segments
Segment Adjusted EBITDA:
Total Adjusted EBITDA	$ (11,975,000)		$ (26,224,000)		$ (24,392,000)	$ (57,363,000)